QL2107

QL2107 is a biosimilar of pembrolizumab developed by Qilu Pharmaceutical. It is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor on T cells, functioning as an immune checkpoint inhibitor. By blocking PD-1, it enhances the immune system's ability to detect and destroy cancer cells. The drug is being developed primarily for the treatment of solid tumors and metastatic non-squamous non-small cell lung cancer (NSCLC), with ongoing clinical trials comparing its efficacy and safety to Keytruda (pembrolizumab). Clinical development includes phase I studies in healthy volunteers and phase III studies in patients with NSCLC[3][4][5][6].